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Abstract Custom-designed patient-speciﬁc implants and
reconstruction plates are to date commonly manufactured
using two different additive manufacturing (AM) technol-
ogies: direct metal laser sintering (DMLS) and electron
beam melting (EBM). The purpose of this investigation was
to characterize the surface structure and to assess the
cytotoxicity of titanium alloys processed using DMLS and
EBM technologies as the existing information on these
issues is scarce. “Processed” and “polished” DMLS and
EBM disks were assessed. Microscopic examination
revealed titanium alloy particles and surface ﬂaws on the
processed materials. These surface ﬂaws were subsequently
removed by polishing. Surface roughness of EBM pro-
cessed titanium was higher than that of DMLS processed.
The cytotoxicity results of the DMLS and EBM discs were
compared with a “gold standard” commercially available
titanium mandible reconstruction plate. The mean cell
viability for all discs was 82.6% (range, 77.4 to 89.7) and
83.3% for the control reconstruction plate. The DMLS and
EBM manufactured titanium plates were non-cytotoxic both
in “processed” and in “polished” forms.
Graphical Abstract
1 Introduction
Large bone defects with variable shapes often pose a
challenge in surgery. To date different materials are used to
strengthen or replace different parts of the skeleton after
trauma, resection of tumours or occasionally when treating
congenital abnormalities. Currently most bony defects are
managed using autologous bone grafts in combination with
metallic and recently also with polymer/composite recon-
struction plates. However, one major drawback of using
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titanium plates is that during surgery such plates have to be
manually manipulated, hence bent and cut to ﬁt the defect
site. This process of adapting stock titanium reconstruction
plates to the bone defect can in some cases be cumbersome
and time consuming, and more importantly, bending of the
plate may predispose to fatigue fractures of the plate.
Recently there has been a rapid development in the area
of customized implants for the treatment of aforementioned
bone defects. Novel additive manufacturing (AM) technol-
ogies allow the pre-fabrication of patient speciﬁc, hence
customized, reconstruction plates using computer tomo-
graphy data of the patient. The major advantage of AM
reconstruction plates is that they do not require any
intraoperative bending and thereby offer a good passive ﬁt
to the defect site, better fatigue resistance and subsequently
shorter operation time [1, 2].
In the literature, some studies [3] have reported that AM-
processed material surfaces often result in a relative rough
surface ﬁnish when compared with conventionally manu-
factured medical constructs. Therefore, in some applications
like artiﬁcial joints the surface of the implant needs to be
manually treated hence polished after the AM-process.
Furthermore surface ﬁnishing is also required to eliminate
surface ﬂaws, which may predispose to fatigue failures. In
this context, Sidambe et al. [3] reported that implant mac-
rostructures and surface ﬁnishing have an affect on the
overall clinical performance of AM implants.
To date a large group of patients have been successfully
treated using customized metal implants that had been
manufactured either using direct metal laser sintering
(DMLS) or electron beam melting (EBM) [1, 4]. Currently,
little is known about the surface structure and biocompat-
ibility of the materials with respect to the AM technologies
and surface treatment.
EBM technology utilizes a high power electron beam
that generates energy to melt powder layer by layer. The
electron beam is managed by electromagnetic coils, which
provide an extremely fast and accurate beam. This allows
several melt pools to be maintained simultaneously. DMLS
technology uses lasers to sinter the metal powder layer by
layer [5, 6]. Currently titanium and cobalt-chrome alloys are
the most commonly used metals in medical AM.
A recent animal study by Stübinger et al. reported no
differences in grade of osseointegration between milled, grit
blasted, etched and DMLS titanium implants [7]. Further-
more, EBM-made titanium alloys have been reported to be
biocompatible [8]. However, there is no information on
whether biocompatibility of DMLS and EBM processed
titanium alloys differ from each other. It can be hypothe-
sised that the ﬁnishing process to eliminate surface ﬂaws
can leave remnants of the ﬁnishing compounds to the grain
boundaries of the metal, which may inﬂuence biocompat-
ibility of the material.
Thus, the objective of this study was to use cytotoxicity
tests to determine the biocompatibility of two different
titanium alloys that were processed and ﬁnished in two
ways and furthermore, to characterize the surface topo-
graphy of the processed titanium discs by scanning electron
microscopy.
2 Materials and methods
Disc shaped TiAL6V4 ELI alloy specimens were manu-
factured using an EBM device (equipment manufacturer
Arcam AB, Mölndal, Sweden and service provider FIT
Fruth Innovative Technologien GmbH, Lupburg, Ger-
many). The aforementioned EBM alloy fulﬁls the ASTM
F136 [9] speciﬁcations. Furthermore, disc specimens were
manufactured using DMLS technology and a Ti64 ELI
alloy (Electro Optical Systems GmbH, Krailling, Germany).
According to the manufacturer’s information, the Ti64
DMLS alloy fulﬁls the ASTM F136 [9] requirements. A
forged stock titanium alloy mandible plate (TICP, Synthes
GmbH, Zuchwil, Switzerland) was used as a reference
sample.
Preliminary metallurgical grinding of the discs was done
using silicon carbide abrasive paper with a FEPA grit size
of P320 to P4000 (ISO 6344). Final grinding was performed
using a 3 µm diamond suspension and a polishing cloth.
Lastly, all discs were puriﬁed using ultrasonic cleaning
(ethanol) for three minutes. The surfaces of the EBM and
DMLS discs were subsequently examined using scanning
electron microscopy (SEM) to assess differences in the
surface microstructure and surface topography.
All of the discs and the control construct were subse-
quently sterilized using a dedicated autoclave in accordance
to the ISO 17664 [10] speciﬁcations before cytotoxicity
testing. The specimens are presented in Fig. 1. The number
of test specimens was as follows: EBM as processed n= 8,
EBM polished n= 8, DMLS as processed n= 8, DMLS
polished n= 6, and the control material specimen. Nominal
test specimen dimensions in the CAD model were: thick-
ness t= 2 mm, diameter d= 17 mm and surface area 560
mm2. Actual average test item dimensions were as follows.
EBM as processed, t= 2.5 mm, d= 17.2 mm, 596 mm2
(6% over nominal value); EBM polished, t= 1.5 mm, d=
16.4 mm, 503 mm2 (10% under nominal value); DMLS as
processed, t= 2.1 mm, d= 17.3 mm, 586 mm2 (5% over
nominal value); DMLS polished, t= 1.8 mm, d= 16.7 mm,
532 mm2 (5% under nominal value).
The test procedure carried out in this study was per-
formed according to the recommendations of the ISO
standards and also the number of the used specimens
and test repeats followed the instructions of these standards
[11–13].
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Surface topography of the specimens was analysed by
measuring Ra values with the Innovatest TR-200 (Maas-
tricht, The Netherlands) measuring equipment. The “EBM
as processed”—specimens were out of the measuring range
of the Innovatest TR-200 equipment and for these speci-
mens the Taylor Hobson Form Talysurf Inductive 120
(Leicester, UK) equipment was used. The Ra values and
standard deviations (SD) of three measurements were
measured.
Positive Bioreaction (Lot: F0D014) (US Pharmacopeia,
Rockville, MD, USA) was used as a positive control. The
Positive Bioreaction test material contains an organo-tin
compound, which, upon release in cell culture tests, causes
cell damage. High-density polyethylene (Lot: H0F046) from
US Pharmacopeia was used as a negative control. High-
density polyethylene is considered to be non-toxic and non-
hazardous. Cell culture medium was used as a blank control.
The extraction of the test items was done according to the
ISO 10993 – 12 recommendations. The test items were
submerged in Eagle’s minimum essential medium with 10%
FBS, at a ratio of 3 cm2/ml medium, at +37± 1 °C for 24 h.
For test items 1, 3 and 4, four tests were performed. Each
repeat consisted of two coin-like pieces. For test item 2, 3
repeats with two pieces were carried out. For test item 5 two
repeats were carried out.
The total surface areas of the test specimens for each
repeat and the medium volumes for extraction (3 cm2/ml)
were as following:
1. Test item 1 with 4 repeats (T11, T12, T13, T14), 11.2
cm2, 3.73 ml
2. Test item 2 with 3 repeats (T21, T22, T23), 11.2 cm
2,
3.73 ml
3. Test item 3 with 4 repeats (T31, T32, T33, T34), 11.2
cm2, 3.73 ml
4. Test item 4 with 4 repeats (T41, T42, T43, T44), 11.2
cm2, 3.73 ml
5. Test item 5 with 2 repeats
T51, 6.9 cm
2, 2.3 ml
T52, 8.4 cm
2, 2.8 ml
The positive control (Positive Bioreaction) and the nega-
tive control (High-density polyethylene) were extracted in cell
culture medium at a ratio of 3 cm2 surface area/ml medium in
same condition as those with the test items. Positive control:
2.6ml (7.8 cm2); negative control: 8 ml (24 cm2).
The culture of L-929 cells was carried out based on
instructions provided by ATCC. Cells were cultured for 2
passages in T75 ﬂask in cell growth medium (Eagle’s
Minimum Essential Medium, 10% FBS, 1% antibiotic/
antimycotic). Thereafter, 1× 104 cells in a volume of 100
µl/per well were transferred to the 96 well microplates. Cells
Fig. 1 a EBM test item as
processed, b EBM test item
polished, c DMLS test item as
processed, d DMLS test item
polished and e commercial
mandible plate (control)
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were cultured in a cell culture incubator (Sanyo MCO 18) in
humidiﬁed 5%CO2 in air at +37 °C for 24 h, so that the
cells formed half-conﬂuent layers. Thereafter, cell culture
medium was replaced by the test item extracts at con-
centrations of 100, 75, 50, 25 and 12.5% diluted in the
normal culture medium as well as in the positive, the
negative and the blank controls for a further 24 h. For
the test specimens, the positive and negative controls, the
extracts from each specimen will be applied to cells eight
times (8 repeats=wells= 1 row). For the blank control
(culture medium only), 16 repeats (2 rows) were used. Row
1 and Row 12 of each plate were not used.
At the end of the experiment time point, culture medium
was replaced by 50 μl MTT solution (1 mg/ml) and cells
were further incubated for 2 h in an incubator. Then MTT
solution was discarded and 100 μl of isopropanol was added
to each well. Thereafter, the plates were shaken gently and
subsequently transferred to a microplate reader (Hidex
Chameleon V) with a 570 nm ﬁlter to read the absorbance
(reference wavelength 690 nm).
To calculate the reduction of viability caused by the test
item compared to the blank the following equation was used:
Viability%= 100×OD570e/OD570b where
OD570e=mean value of the measured optical density of
the 100% extracts of the test item and
OD570b=mean value of the measured optical density of
the blanks.
According to the ISO standard 10993, when cell viability
is reduced to <70% of the blank, the test item is considered
to have cytotoxic potential.
3 Results
Surface roughness (Ra) was higher for EBM processed than
for DMLS processed (Ra 29.94 and 7.867). Polishing
lowered the surface roughness (EBM: 0.085 and DMLS:
0.028) (Table 1). Figures 2–4 show magniﬁed surface ﬁn-
ishes of the processed and polished test specimens. Figure 2
shows EBM and DMLS discs that had been manufactured
using different titanium particle sizes, and thus, resulted in
different surface topographies. The DMLS manufacturing
process used smaller titanium alloy beads than the EBM
process. Figure 3 shows a larger magniﬁcation of the disc
surfaces, compared with the control materials surface. Both
AM processes resulted in surface ﬂaws. Figure 4 shows that
the polished EBM and DMLS have homogeneous micro-
structures with some small defect/ﬂaw areas.
The viability of blank control (cells cultured with only
normal medium) was set as 100%. The viability of cells
treated with test item extract (100% without dilution) was
then compared with viability of the blank.
Fifty percent extract of the same test specimen means 1
volume of test item extract plus 1 volume of normal culture
medium. All the tested items were found to be non-
cytotoxic. The cell viability of test item 1 (Ti64 ELI EOS
DMLS as processed): 89.67%; the cell viability of test item
2 (Ti64 ELI EOS DMLS polished): 77.40%; the cell via-
bility of test item 3 (TiAL6V4 ELI EBM as processed):
Table 1 Surface roughness (Ra) of materials processed with EBM
and DMLS methods
Process Ra SD
EBM as processed 29.94 1.721
EBM polished 0.085 0.007
DMLS as processed 7.867 0.084
DMLS polished 0.028 0.003
Reference 0.491 0.016
Reference material: Forged stock titanium alloy mandible plate. SD
standard deviation
Fig. 2 SEM images of the sur-
face ﬁnishes of as processed
a EBM and b DMLS test spe-
cimens (original magniﬁcation:
×100)
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80.74%; the cell viability of test item 4 (TiAL6V4 ELI
EBM polished): 82.65%; the cell viability of test item 5
(Synthes lock mandible plate): 83.30%. Viability (%) of
L929 cell 24 h after incubation with the extractions of the
test items and the controls is summarized in Table 2.
4 Discussion
Recently there has been a rapid progress in the development
of implant materials for the treatment of bony defects. The
aim of this study was to investigate the in vitro cytotoxicity
of titanium discs that were produced using DMLS and EBM
technology. The acquired discs were subsequently com-
pared to a control titanium reconstruction plate commonly
used in maxillofacial surgery. In addition, the surface tex-
tures of the DMLS and EBM processed titanium alloys
were characterized. Information of the surface texture of the
AM-processed titanium helps our interpretation of the
possible risks of fatigue failures which may initiate from the
surface ﬂaws of the material.
DMLS technology has been used to manufacture custo-
mized meshlike orbital implants [4] and mesh for bone
augmentation [2]. Acetabular cup and femoral knee
implants made by EBM are commercially available [14].
Also bone screws made using DMLS are in the market [15].
Fig. 3 SEM images of the surfaces of the as processed a control plate, and b EBM and c DMLS items (original magniﬁcation: ×500)
Fig. 4 SEM images of the
surfaces of polished a EBM and
b DMLS discs. Both samples
contained defect areas of either
not fully melted powder or gas
pores in form of small fractures
(white arrows), (original
magniﬁcation: ×500)
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The Ti-6Al-4V brand used, EBM or DMLS design, pol-
ishing and sterilization all affect the implant macro-, micro-
and nano-structure and chemical composition. Therefore, it
was necessary to test the individualized implants for cyto-
toxicity using positive and negative controls and mass-
produced clinical control implants. This was technically
perfectly done using the current ISO standards.
Microscopical examination showed metal beads, which
had not been melted in the DMLS or EBM process. Close to
the titanium beads, some surface ﬂaws could be detected.
Surface ﬂaws may behave as initiation areas for fatigue
fractures if the implant is dynamically loaded like in
mandible reconstruction. Polishing of the material surface
seemed to remove majority of the surface ﬂaw, although
minor porosities could still be detected at the surface. Por-
osities could be either gas pores from trapped gas in the
manufacturing process or unmelted powder beads.
All tested items were found to be non-cytotoxic after
titanium had been subjected to the manufacturing, polishing
and sterilization steps. It thus seems that DMLS and EBM
produced individualized, custom-made implants do not
cause any short-term adverse effects in form of cytotoxicity
in peri-implant cells.
DMLS and EBM produced implants integrate to their
surrounding tissues via their surface structures. Therefore,
toxicity of the implants might impair both hard bone tissue
(osseo)integration and soft tissue integration in short- and
long-term [16]. Short-term cell and tissue damage might
induce an acute inﬂammatory reaction, which might cause
local site-speciﬁc damage and symptoms and contribute to
the formation of an implant capsule and thus impair
osteointegration, stability and the long-term outcome of the
implant. Extraction method used according to the ISO
standard 10993 – 1, 3, 5 gave assuring results considering
the fact that the custom-made implant comes into contact
with body ﬂuids and cells upon implantation to the reci-
pient. This interaction with the environment might initiate
dissolution of harmful implant-derived products not neces-
sarily derived from the parent biocompatible titanium
compound [17] but from the substances and changes used
and produced during additive manufacturing process. The
EBM processed material used in this study showed a more
porous structure than the DMLS surface and this might have
an affect on the micromechanical locking and tissue-
adhesion to the implant.
5 Conclusions
All the test pieces produced by Additive Manufacturing
(AM) technologies and tested in the present study, seemed
non-cytotoxic and would from this point of view be safe for
clinical use as an alternative to the mass produced products
which do not provide the patient- and site-speciﬁc adapta-
tion and ﬂexibility, which is characteristic to AM products.
Surface of the titanium alloy showed some ﬂaws, which
were eliminated by polishing the surface. Surface ﬁnishing
which in many clinical cases is required to ﬁnalize at least
some surface areas of the AM implant does not inﬂuence to
cytotoxicity of an implant.
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